Acquisition to enhance cell biology capabilities and accelerate evaluations of potential new drug targets
HUNTSVILLE, Ala., April 11, 2023 /PRNewswire/ — Discovery Life Sciences™ (Discovery), Biospecimen and Biomarker Specialists™, has acquired Seattle-based ReachBio Research Labs (ReachBio®), a company specializing in biomarker-based assays. in cells, predictive hematotoxicity and drug detection services. This acquisition will allow Discovery to scale its established drug discovery and preclinical development offerings to give clients access to a broader range of innovative and specialized cell biology services.
Known as The Cell Biology Experts™, ReachBio was founded in 2007. The company’s expertise spans primary cell biology with a particular focus on blood and bone marrow stem cell assays. ReachBio supports its clients’ basic research in multiple therapeutic areas. It provides assessments of the immune response and toxicity of novel drug targets in hematologic diseases, cell and gene therapy, immunology, oncology, and immuno-oncology.
Discovery has increased its strategic investments in innovative preclinical development services. The company’s acquisition of ReachBio accelerates the continued growth of its cell biology and toxicology services, complementing previous acquisitions of Discovery from IVAL and Corning’s Gentest® business unit. ReachBio’s expertise in cell biology assay development and interpretation services are widely used to assess the potential toxicity of new drug candidates, enabling clients to make early and informed decisions about the safety and potential efficacy of new drug candidates. candidate drugs.
Passage of the FDA’s Modernization Act 2.0 last year reduced the requirement for animal testing, enabling ReachBio’s advanced predictive colony formation assays to ultimately expedite the submission of new drug applications in FDA investigation of their customers.
“We are delighted to welcome ReachBio to the Discovery family,” said Discovery CEO Glenn Bilawsky. “ReachBio’s expertise in cell-based assays and drug screening well positions us to capitalize on recent regulatory changes and continue to meet the rapidly evolving needs of the pharmaceutical industry.”
“Joining forces with Discovery is a great opportunity for us,” said Emer Clarke, Ph.D., ReachBio’s chief scientific officer. “We share Discovery’s passion for science and believe that combining our expertise in cell-based assays and drug detection with Discovery’s extensive multi-omics capabilities will enable us to provide a broader and more strategic range of services to pharmaceutical clients. Together, we will further accelerate the advancement of drug discovery and development to improve patient outcomes.”
About Discovery Life Sciences
Discovery Life Sciences is the company of specialist biospecimens and biomarkers, combining one of the world’s largest commercial biospecimen inventory and acquisition networks with preeminent multi-omics biomarker service laboratories, including genomics, tissue biomarker, proteomics and flow cytometry to accelerate new biomarker-supported therapies and complementary diagnostic programs for cancer, infectious diseases, and other rare and complex conditions.
Through AllCells®, our cell and gene therapy division, we maintain the largest pool of recoverable donors to supply fresh and cryopreserved human cell materials of clinical grade and for Research Use Only (RUO) to support programs of cell and gene therapy at any stage of development and on any scale.
Discovery’s leading scientific expertise, scale of global operations, and innovative use of today’s technologies enable clients to deliver results for critical research and development decisions at market-leading speed. We are Science at your Service™! For more information, visit dls.com.
Logo – https://mma.prnewswire.com/media/1022478…
View original content: https://www.prnewswire.com/news-releases/discovery-life-sciences-adquiere-reachbio-research-labs-301794495.html
